Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Dr Reddy's expands...

    Dr Reddy's expands injectable portfolio with acquisition of 42 ANDAs in US

    Farhat NasimWritten by Farhat Nasim Published On 2019-04-15T10:00:34+05:30  |  Updated On 16 Aug 2021 12:20 PM IST

    This transaction will help augment Dr Reddy's Labs injectables product portfolio in the U.S. market and globally.


    Hyderabad: Dr Reddy's Laboratories has signed a definitive agreement to acquire a portfolio of 42 approved, non-marketed Abbreviated New Drug Applications (ANDAs) in the United States.


    The portfolio includes more than 30 generic injectable products. These products will require technology transfers and could be launched in the next one or two years.

    "The acquisition is in line with our stated strategy to significantly enhance our portfolio in our chosen growth markets," said company's Chief Executive Officer Erez Israeli.

    Also Read: Dr Reddys launches B2B Customer Service Portal XCEED


    "This transaction will help augment our injectables product portfolio in the U.S. market and globally," he added.


    The value of total addressable market for these products in the United States was about 645 million dollars (about Rs 4,470 crore) last calendar year, according to IQVIA.

    IQVIA, earlier known as Quintiles and IMS Health Inc, is an American multinational company serving the combined industries of health information technologies and clinical research.

    Also Read: Dr Reddys recalls 2770 bags of Levetiracetam Sodium Chloride injection in US market

    ANDAs portfolioDr Reddy'sDr Reddy's LabsDr Reddys LabGeneric InjectableIMS Healthinjectable portfolioinjectablesIQVIATechnologiesUSY. S. Rajasekhara Reddy
    Source : ANI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok